Effects of cyproterone acetatea combined with rosiglitazone and metformin therapy in severe insulin resistant patients with polycystic ovary syndrome

Objective To discuss the therapeutic effects of cyproterone acetatea(CPA) combined with metformin and/or rosiglitazone on endocrine and metabolism in PCOS patients with severe insulin resistance.Methods In First Affiliated Hospital of Harbin Medical University,84 PCOS patients with severe insulin resistance from January 2007to June 2008 were randomly divided into group A,B and C.33 patients in group A were given CPA combined with metformine and rosiglitazone for 3 months;26 patients in group B were given rosiglitazon and CPA for 3 months.25 patients in group C were given metformin and CPA for 3 months.The clinical feature,reproductive hormone,serum glucose and insulin levels were observed before and after treatment.Results After 3 months treatment,the serum T level decreased in A,B and C groups,but there was no significant difference among 3 groups(P0.05).The index of glucose metabolism and insulin resistance were significantly decreased after treatment in three groups,but there was no significant difference among 3 groups(P0.05).Moreover,group A therapeutic effects on Homa IR、Homaβ、AUC_ INS were much better than group B、C,there being significant difference(P0.05).Conclusion CPA combined with rosiglitazone and metformin used to treat PCOS with severe insulin resistance and hyperinsulinemia more effectively than rosiglitazone and metformin respectively.